Drug Search Results
More Filters [+]

Dacomitinib

Alternative Names: dacomitinib, pf-00299804, pf-299, pf299, pf 299, vizimpro
Latest Update: 2024-09-04
Latest Update Note: Clinical Trial Update

Product Description

Dacomitinib is a multi-kinase receptor inhibitor used in the therapy of cases of non-small cell lung cancer that harbor activating mutations in the epidermal growth factor receptor gene (EGFR). Dacomitinib is associated with high rate of transient serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dacomitinib)

Mechanisms of Action: TK Inhibitor,EGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Austria | Bangladesh | Belgium | Canada | Chile | Colombia | Croatia | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Small Cell Lung Cancer | Oncology Unspecified

Known Adverse Events: Alopecia | Stomatitis | Pruritus | Paronychia | Diarrhea

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dacomitinib

Countries in Clinic: China, Hong Kong, Italy, Japan, Korea, Malaysia, Netherlands, Poland, Singapore, South Korea, Spain, Thailand

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer

Phase 2: Abnormalities, Multiple|Head and Neck Cancer|Hodgkin Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Vision, Low

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DRUP

P2

Recruiting

Hodgkin Lymphoma|Abnormalities, Multiple|Multiple Myeloma|Lymphoma, Non-Hodgkin|Vision, Low|Lymphoma, B-Cell

2027-09-01

ATORG-003

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2026-03-31

STCC-01

P2

Recruiting

Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer

2025-07-01

A randomized, non-comparative, phase II study investigating the best epidermal growth factor recept

P2

Active, not recruiting

Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

2023-11-20

Recent News Events